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It is with great interest that we read the article by Yindom et al. who performed an observational 
study reporting a high prevalence of CMV DNAemia among older children and adolescents 
with perinatally acquired human immunodeficiency virus (PHIV), and an independent 
association of DNAemia >1000 copies/mL with stunting and reduced lung function[1]. We 
wish to highlight some caveats that in our opinion are pertinent when interpreting the reported 
findings. 
The authors investigated the hypothesis that poorly controlled CMV co-infection acquired in 
childhood could contribute to comorbidities such as chronic lung disease (CLD), but the 
evidence presented does not adequately test this hypothesis. First, adjustment for potential 
confounders was limited. In the same population, late initiation of antiretroviral treatment and 
poor nutrition were also associated with decreased lung function [2]. CLD described in people 
living with HIV (PLWH) is also associated with a history of frequent respiratory tract 
infections with clinical and radiological findings suggestive of repeated bacterial infections[3]. 
The interplay between CMV and HIV is complex, and it is questionable whether subclinical 
CMV replication in the bloodstream is a causal agent leading to complications or merely a 
marker of impaired cellular immunity[4, 5]. The observed association could, therefore, be 
confounded by associated defects in cell-mediated or innate immunity, precluding sufficient 
control of both CMV and bacterial infections. For example, alveolar macrophage (AM) 
microbicidal responses are impaired in PLWH, despite adequate antiretroviral therapy and 
independent of CD4 count, predisposing to bacterial pneumonia [6]. However, AM from CMV 
seropositive individuals are permissive to CMV re-activation and lytic replication, and 
potentially associated interference with immunological function[7, 8]. Therefore, CMV 
replication in the lung in the absence of overt pneumonitis could indeed predispose to repeated 
episodes of bacterial infection, but the data reported in this study cannot confirm this as the 
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direct evidence of CMV replication in the lungs was not studied. Whilst we recognize the 
extreme difficulties in obtaining lower respiratory tract specimens in this setting, this does pose 
a barrier to attributing causality to CMV. 
Additionally, the authors reported CMV DNAemia as copies/mL. The World Health 
Organization International Standard for CMV recommends calibrating results to international 
units per ml (IU/ml) to prevent large inter-laboratory heterogeneity. This variability is not only 
problematic for laboratories, but also clinicians and patients, and can be as large as 6 log10[9, 
10]. Therefore, reported DNAemia values are difficult to interpret, and viral loads cannot be 
translated into other settings. 
Considering these points, CLD is likely to have a multifactorial aetiology in this population, 
and although an interesting hypothesis, an independent association between CMV DNAemia 
and CLD remains unconfirmed in this population. We agree that further work is required to 
refine our understanding of CMV DNAaemia and CLD. This will require sampling the lower 
respiratory tract, calibrating quantitative CMV viral load results to the international standards 
and including other relevant potential confounders in time-varying multivariable analysis, 




No funding was received 
 
Conflict of Interest:  









1. Yindom LM, Simms V, Majonga ED, et al. Unexpectedly High Prevalence of 
Cytomegalovirus DNAemia in Older Children and Adolescents With Perinatally 
Acquired Human Immunodeficiency Virus Infection. Clin Infect Dis 2019. 
2. Rylance S, Rylance J, McHugh G, et al. Effect of antiretroviral therapy on 
longitudinal lung function trends in older children and adolescents with HIV-
infection. PLoS One 2019; 14(3): e0213556. 
3. Desai SR, Nair A, Rylance J, et al. Human Immunodeficiency Virus-Associated 
Chronic Lung Disease in Children and Adolescents in Zimbabwe: Chest Radiographic 
and High-Resolution Computed Tomographic Findings. Clin Infect Dis 2018; 66(2): 
274-81. 
4. Freeman ML, Lederman MM, Gianella S. Partners in Crime: The Role of CMV in 
Immune Dysregulation and Clinical Outcome During HIV Infection. Curr HIV/AIDS 
Rep 2016; 13(1): 10-9. 
5. Gianella S, Massanella M, Wertheim JO, Smith DM. The Sordid Affair Between 
Human Herpesvirus and HIV. J Infect Dis 2015; 212(6): 845-52. 
6. Collini PJ, Bewley MA, Mohasin M, et al. HIV gp120 in the Lungs of Antiretroviral 
Therapy-treated Individuals Impairs Alveolar Macrophage Responses to 
Pneumococci. Am J Respir Crit Care Med 2018; 197(12): 1604-15. 
 5 
7. Poole E, Juss JK, Krishna B, Herre J, Chilvers ER, Sinclair J. Alveolar Macrophages 
Isolated Directly From Human Cytomegalovirus (HCMV)-Seropositive Individuals 
Are Sites of HCMV Reactivation In Vivo. J Infect Dis 2015; 211(12): 1936-42. 
8. Onno M, Pangault C, Le Friec G, Guilloux V, Andre P, Fauchet R. Modulation of 
HLA-G antigens expression by human cytomegalovirus: specific induction in 
activated macrophages harboring human cytomegalovirus infection. J Immunol 2000; 
164(12): 6426-34. 
9. Kraft CS, Armstrong WS, Caliendo AM. Interpreting quantitative cytomegalovirus 
DNA testing: understanding the laboratory perspective. Clin Infect Dis 2012; 54(12): 
1793-7. 
10. Preiksaitis JK, Hayden RT, Tong Y, et al. Are We There Yet? Impact of the First 
International Standard for Cytomegalovirus DNA on the Harmonization of Results 
Reported on Plasma Samples. Clin Infect Dis 2016; 63(5): 583-9. 
 
